1 results ยท Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Safety and Efficacy of scAAV9/AGA Gene Therapy in Participants With Aspartylglucosaminuria (AGU)Aspartylglucosamidase (AGA) deficiency, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Nutritional and Metabolic Diseases, aspartylglucosaminuria, hereditary disease, inborn errors of metabolism, lysosomal storage disease, metabolic diseaseNot yet recruitingPhase 1 / Phase 22026-04-15NCT07530796